Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AntiFib-rtPA6
- Development stage
- Preclinical
- Lead developer
- Etablissement Français du Sang
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
AntiFib-rtPA6 is an experimental, preclinical-stage fibrin-targeted fusion protein designed for the treatment of arterial and venous thrombosis, including pulmonary embolism (PE) and acute ischemic stroke. Developed by researchers at INSERM and the Etablissement Français du Sang (EFS), the molecule consists of a high-affinity, fibrin-specific monoclonal antibody fused to two catalytic domains of recombinant tissue plasminogen activator (rtPA) via non-cleavable linkers. This targeted approach concentrates thrombolytic enzymatic activity directly within fibrin-rich thrombi, enhancing local efficacy while minimizing systemic exposure to reduce the risk of bleeding and neurotoxicity. In ex vivo studies, AntiFib-rtPA6 demonstrated strong and specific binding to human and murine fibrin without targeting fibrinogen, and achieved thrombus lysis in patient-derived PE and stroke samples comparable to free rtPA.
- Other names
- AntiFib-rtPA
02
Targets
Fibrin (Factor Ia)PAI-1 (Plasminogen activator inhibitor type 1)PAI-2 (Plasminogen activator inhibitor-2)
Beyond the preview
Go deeper on AntiFib-rtPA6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AntiFib-rtPA6.